Phytomedicine Submission Guide

This page was researched from Phytomedicine's author guidelines, Elsevier editorial-policy materials, Clarivate JCR data, SciRev community reports, and Manusights internal analysis of submissions to Phytomedicine and adjacent venues.

Source limitations: Elsevier can update portal fields, ethics requirements, article-type instructions, and open-access pricing after this review date, so authors should verify final administrative details against the live Guide for Authors. This page is for the fit decision official instructions do not answer: whether the manuscript is a therapy-oriented natural-product pharmacology paper with mechanism, standardization, and translational evidence strong enough for Phytomedicine.

In the 100-manuscript Manusights sample used for this guide, 22 were natural-product pharmacology papers where the recurring pre-upload risk was a gap between the plant material, chemical fingerprint, mechanism evidence, in-vivo or clinical validation, and therapeutic claim. The strongest packages made the voucher specimen, HPLC or related characterization, dose logic, mechanism readout, and cover-letter fit visible before the editor had to infer them from the methods.

Through our diagnostic review, we treat the botanical authentication, chemical fingerprint, dose logic, mechanism assay, in-vivo or clinical evidence, safety data, and cover letter as one Phytomedicine-facing package rather than as separate upload tasks.

Source: Phytomedicine Guide for Authors, accessed May 2026.

Source: Phytomedicine author guidelines.

Use this page when deciding:

• whether the natural-product pharmacology contribution is substantive

• whether plant standardization is rigorous

• whether in-vivo validation is included

• a clear natural-product pharmacology contribution

• validated plant identification and standardized extracts

• in-vivo validation

• mechanism of action

• a cover letter establishing the contribution

• Descriptive activity reports without mechanism.

• Missing standardization of plant material.

• Weak in-vivo validation.

• Pure chemistry without pharmacology focus.

One failure pattern we see is the extract-first abstract: the manuscript leads with plant or compound identity and endpoint activity, but the therapeutic mechanism, dose logic, and standardization method are scattered later. For Phytomedicine, editors need to see the therapy-oriented pharmacology claim before they invest reviewer time.

Phytomedicine is a flagship natural-product pharmacology journal.

Standardization standard: the journal differentiates from broader pharmacology venues by demanding rigorous plant material standardization.

In-vivo expectation: editors expect animal models or comparable validation.

The 40-50% desk rejection rate: decisive editorial screen.

The strongest Phytomedicine cover letters establish:

• the natural-product pharmacology contribution

• the plant standardization

• the in-vivo validation

• the mechanism of action

Phytomedicine submissions go through Elsevier Editorial Manager at Editorial Manager submission portal. Initial setup requires an Elsevier account; ORCID is recommended for the corresponding author. The journal is published in affiliation with the European Scientific Cooperative On Phytotherapy (ESCOP) and accepts unsolicited Research Papers and Reviews on specified plant extracts, phytopharmaceuticals, and isolated constituents.

Original papers should not exceed 12-15 typewritten pages or 5,000 words including references, tables, and figures; references should not exceed 30 (except for review articles). Full guide at the Phytomedicine author page.

Phytomedicine requires these at first submission:

• Cover letter explicitly establishing the therapeutic relevance and reproducible pharmacological activity (the journal differentiates from generic ethnopharmacology venues by demanding defined and consistent quality)

• Plant material authentication statement with voucher specimen deposition reference (for botanical identification verification)

• Quality-control documentation for the plant extract or isolated constituent (HPLC fingerprint, marker compound quantification, batch consistency data)

• Declaration of competing interests for all authors

• Generative AI usage declaration covering manuscript preparation and figure generation

• Ethics approval statement for animal-research or human-clinical studies with explicit IACUC or IRB reference

• Data availability statement with repository links for clinical trial data, pharmacokinetic measurements, or analytical method validation

• Manuscript within the 12-15 page (5,000 word) cap for original papers, with reference count under 30

• CRediT author contributions statement

• Four or more suggested reviewers with no recent collaboration history

For Phytomedicine submissions, the most common artifact-related desk-reject is missing plant material authentication or quality-control documentation. The journal's ESCOP affiliation drives a strict standard for botanical identification verification; submissions without voucher specimen references or chemical fingerprinting are commonly returned for revision before scope screen.

For Phytomedicine submissions, the editorial timeline runs through four phases. The journal's therapy-oriented focus weights reproducible pharmacological activity over descriptive ethnobotanical observation.

Day 0 to 5: Editorial Manager intake and editor assignment

Elsevier intake handles format compliance plus the plant-authentication, quality-control, and ethics-statement checks. The handling Editor assignment lands within 5 days; phytomedicine papers route to subject editors matching the therapeutic area (cardiovascular, oncology, anti-inflammatory, antimicrobial, neurological, metabolic). The most common Day 0-5 hold-up: missing voucher specimen references or chemical-fingerprint documentation for the plant extract.

Day 5 to 21: Editor scope and reproducibility screen

Phytomedicine's editor filter prioritizes specified plant extracts with defined and consistent quality assuring reproducible pharmacological activity. The most common Day 5-21 desk reject in our review work: studies on poorly characterized plant extracts where the chemical composition or batch consistency cannot be reproduced, ethnobotanical surveys without pharmacological mechanism, and clinical reports on commercial herbal products without explicit extract specification.

Week 3 to 9: Peer review

Single anonymized review process with at least 2 reviewers. Reviewer mix typically includes one phytochemistry or pharmacognosy expert plus one pharmacology or clinical specialist. Submissions missing dose-response data, mechanism-of-action analysis, or comparison against established phytopharmaceuticals extend reviewer dialogue by 3-5 weeks.

Week 9 to 18: Decision, revision, and production

Major revision is the standard first decision at Phytomedicine. Revision rounds typically settle at 2 (rarely 3 for accepted papers). Total submission-to-acceptance: 4-7 months for accepted papers. Hybrid open-access option available with APC at acceptance.

• Is Phytomedicine a good journal?

Before upload, run your manuscript through a Phytomedicine standardization check.

For a broader file-level scan before upload, use the Manusights AI manuscript review to catch readiness gaps across framing, methods, and journal fit. We do not train models on submitted manuscripts.

Across natural-product manuscripts targeting Phytomedicine, three recurring decision risks matter most across submissions that the journal's editors filter out at the desk-screen stage. (Per Elsevier published guidelines and the ConPhyMP (Best Practice in Chemical Characterisation of Extracts) consensus that Phytomedicine has formally adopted, the journal publishes innovative studies on efficacy / safety / quality / mechanisms of specified plant extracts, phytopharmaceuticals, and isolated constituents with defined and consistent quality assuring reproducible pharmacological activity;

explicitly desk-rejects manuscripts with phytochemically non-sufficiently characterized extracts (chemoprofile by HPLC / GC / NMR + quantitation of markers required); runs approximately 40-50 percent desk-rejection rate; treats standardization as part of the claim rather than as methods footnote.

In our experience, the recurring desk-screen issues cluster around descriptive activity reports without mechanism, missing standardization, and weak in-vivo validation.) Use the three checks below before you open Editorial Manager Phytomedicine upload slot.

Descriptive bioactivity report without mechanism of action

Across Phytomedicine-targeted manuscripts, we consistently see authors submit work that reports a plant extract or isolated compound has a bioactivity (anti-inflammatory, antioxidant, antimicrobial, anticancer, neuroprotective, hepatoprotective, antidiabetic, anti-hypertensive, immunomodulatory) demonstrated by standard activity assays (MTT viability, DPPH antioxidant, MIC for antimicrobial, tumor-cell-line growth inhibition, LPS-stimulated cytokine reduction, glucose-uptake assay, blood-pressure measurement) but stops at the activity observation without mechanism-of-action investigation. Phytomedicine handling editors specifically check whether the manuscript:

• identifies the molecular target or pathway responsible for the activity (specific protein target with named assay: kinase inhibition with named kinase + IC50

• receptor binding with named receptor + Ki

• enzyme inhibition with named enzyme + Lineweaver-Burk analysis

• pathway activation with named signaling cascade verified by Western blot / qPCR / reporter assay

• transcription-factor activation with named TF + EMSA / ChIP

• cell-cycle / apoptosis pathway with named markers)

• validates the mechanism with orthogonal approaches (pharmacological inhibitor + genetic knockdown + rescue experiment, or competitive binding + cellular thermal shift assay + molecular docking + site-directed mutagenesis)

• demonstrates dose-response with full IC50 / EC50 curves and Hill-slope analysis

• rules out off-target effects with named counter-screens

• and connects the mechanism to the observed bioactivity with explicit chain of inference

Manuscripts that report activity without mechanism get desk-rejected within days as "descriptive activity report" with redirect to: Journal of Ethnopharmacology (broader ethnopharmacological scope including more descriptive work), Phytotherapy Research (broader herbal-medicine scope), Journal of Natural Products (chemistry-focused with structural characterization emphasis), Planta Medica (broader natural-products), Fitoterapia (broader phytotherapy), Pharmaceutical Biology (broader pharmacology of natural products), or specialty venues for the specific indication.

The fix is to design the study with mechanism investigation from the start (not add mechanism after activity is observed), name the specific molecular target hypothesis in the introduction, validate the target with at least 2 orthogonal approaches, demonstrate full dose-response with Hill-slope analysis, rule out off-target effects with appropriate counter-screens, and structure the abstract around the mechanism-with-activity-as-consequence framing rather than activity-without-mechanism.

Check whether your Phytomedicine mechanism evidence supports the activity claim →

Plant material is not standardized

We frequently see Phytomedicine manuscripts arrive with insufficient plant-material standardization and extract characterization that the journal's adoption of the ConPhyMP (Consensus statement on the Phytochemical Characterisation of Medicinal Plant extracts) consensus requires.

Phytomedicine editors apply ConPhyMP standards at desk, checking for:

• botanical authentication with explicit voucher specimen deposition in a named herbarium (with herbarium code per Index Herbariorum and accession number

• ITS / matK / rbcL DNA barcoding if morphological identification is ambiguous

• named botanist who performed identification with institutional affiliation)

• plant-material provenance (geographic origin with GPS coordinates, collection season with date, plant part used, growth conditions if cultivated, post-harvest processing)

• extract preparation reproducibility (solvent system with grade and supplier, extraction method with extraction ratio, extraction temperature and time, drying method, yield)

• chemical fingerprint of the extract (HPLC chromatogram with named column / mobile phase / detection wavelength / retention times for marker compounds

• GC-MS chromatogram for volatile components

• NMR fingerprint where structural complexity warrants

• UV-Vis spectrum for chromophore-rich extracts)

• quantitation of marker compounds (HPLC-UV / HPLC-DAD / UPLC-MS quantitation of at least 3-5 named markers with validated method per ICH Q2(R1): linearity / range / accuracy / precision / specificity / LOD / LOQ

• mg-per-gram or percent-by-weight reported)

• reference-compound traceability (CAS registry numbers, supplier and catalog numbers, purity certificates for reference standards)

• reproducibility evidence (multi-batch analysis showing batch-to-batch variation within acceptable limits)

Manuscripts with botanical-name-only identification without voucher, with "ethanol extract" without solvent grade or extraction ratio, with claims about "polyphenols" or "flavonoids" without HPLC quantitation of named compounds, or with marker quantitation by total-content assays (Folin-Ciocalteu, aluminum-chloride) without specific-compound HPLC face desk rejection within the 40-50 percent window.

The fix is to deposit voucher specimens before drafting, follow ConPhyMP guidelines for chemical characterization (the published consensus document is the operational standard), validate the HPLC quantitation method per ICH Q2(R1), report at least 3-5 marker compounds with named identity and quantitation, and document multi-batch reproducibility.

Check whether your Phytomedicine plant-material standardization meets the ConPhyMP bar →

Therapeutic claim rests on in-vitro data only

The third recurring pattern in Phytomedicine-targeted manuscripts is therapeutic-relevance claims supported only by in-vitro evidence when the journal's scope specifically covers efficacy of phytopharmaceuticals with defined and consistent quality assuring reproducible pharmacological activity, which implies in-vivo or clinical validation for therapeutic claims.

Phytomedicine editors specifically check whether:

• therapeutic claims (anticancer, neuroprotective, hepatoprotective, antidiabetic, antihypertensive, antimicrobial-in-infection, anti-inflammatory-in-disease) are supported by in-vivo evidence in appropriate animal models (named disease model with disease-specific induction protocol, named strain and source, appropriate sample size with power calculation, randomization, blinded outcome assessment, dose-response with bioavailability data, positive control with named clinical-standard comparator, pharmacokinetics with at least Cmax / Tmax / AUC / t-half)

• pharmacokinetic data document the active compounds reach the relevant tissue at therapeutic concentrations

• safety / toxicity data demonstrate the dose-response window between efficacy and toxicity

• mechanism evidence in vivo (not just in vitro target validation) confirms the mechanism is operative at therapeutically-achievable concentrations

• clinical evidence (if available) follows ICH-E6 GCP, CONSORT for RCTs, named registration

• the in-vivo / clinical evidence supports the specific therapeutic claim made in the abstract

Manuscripts with only in-vitro data and broad therapeutic claims face desk rejection or major revision demanding in-vivo data, which typically takes 12-18 months of additional work.

The fix is to either generate in-vivo evidence with appropriate animal model before submission (planned at study inception, not added later), restrict therapeutic claims to what the data support (in-vitro evidence supports cellular-mechanism claims, not therapeutic claims), or route in-vitro-only mechanistic work to chemistry-focused venues (Journal of Natural Products, Bioorganic & Medicinal Chemistry, Natural Product Communications) where in-vitro mechanism without in-vivo validation is acceptable.

Check whether your Phytomedicine manuscript is submission-ready →

Clarivate JCR 2024 bibliometric data places Phytomedicine among top natural-product pharmacology journals.

Use these nearby guides when the target journal is still uncertain:

• Remote Sensing of Environment Submission Guide

• Earth Science Reviews Submission Guide

• Journal of Biogeography Submission Guide

• Global Ecology and Biogeography Submission Guide

• Fuel Submission Guide

• Water Research Submission Guide

• Journal of Cleaner Production Submission Guide

• Food Hydrocolloids Submission Guide

• Microorganisms Submission Guide

• Frontiers In Microbiology Submission Guide

In pre-submission diagnostics for Phytomedicine, we start with the chain from material identity to biological claim. A strong paper names the plant or compound cleanly, shows how the material was authenticated, explains what was measured, connects the assay result to a plausible mechanism, and states why the result matters for phytotherapy or natural-product pharmacology. A paper that has activity data but no characterization, no dose logic, or no mechanism usually reads like an early screening report rather than a Phytomedicine submission.

For this journal, standardization is not a methods footnote. It is part of the claim. If the manuscript studies a plant extract, the reader needs to know what material was collected, how it was identified, how the extract was prepared, and which chemical markers support reproducibility. If the manuscript studies an isolated compound, the purity, source, and analytical confirmation need to be easy to find. We coach authors to make the characterization visible before editors have to ask whether the biology can be reproduced.

Three patterns create avoidable risk. The first is a missing voucher, unclear taxonomic naming, or weak authentication trail. The second is a pharmacology claim built on one cell-line assay without dose-response, rescue, pathway, or animal evidence. The third is a discussion that cites general herbal-medicine literature but does not place the finding against recent Phytomedicine papers in inflammation, metabolism, neuroprotection, antimicrobial activity, or other relevant therapeutic areas.

The strongest Phytomedicine submissions make the editor's first screen unusually easy. The abstract states the natural-product entity, model system, primary effect size, mechanism, and translational implication without forcing the editor to reconstruct the story. The introduction names the pharmacological gap, not just the disease area. The cover letter adds one compact fit argument: why this paper belongs in Phytomedicine rather than a general pharmacology, ethnopharmacology, chemistry, or plant-science journal.

Before submission, check whether the manuscript can answer five editor questions in under two minutes: what natural product is being studied, how reproducible is the material, what biological system supports the claim, what mechanism explains the result, and why the paper advances therapeutic or pharmacological understanding. If any answer is buried or speculative, fix that before uploading.

Phytomedicine triage is usually decided before a full technical read. Editors can reject quickly if the abstract sounds like generic extract screening, if the methods do not make the material reproducible, or if the conclusion overstates clinical relevance from preliminary models. We coach authors to put the strongest fit signals in the abstract, graphical logic, methods opening, and final paragraph rather than relying on reviewers to infer them later.

Authority for this journal is field-specific. A credible submission shows that the authors understand current natural-product pharmacology standards, not just the local plant, compound, or disease model. In practice, that means citing recent Phytomedicine work in the same therapeutic or mechanistic neighborhood and explaining how the new manuscript extends the conversation with better standardization, stronger validation, or a cleaner mechanism.

Editors usually check whether the natural product is reproducibly defined, whether the biological model supports the therapeutic claim, and whether the mechanism is more than a post-hoc pathway label. If the abstract does not answer those three questions, the submission can look preliminary even when the experiments are technically careful.

• If the manuscript is already in Editorial Manager, use the Phytomedicine Under Review status guide to interpret the status and plan follow-up timing.